Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to verify the effect of the intervention of a program of physical exercises and health education in women with breast cancer undergoing chemotherapy.

Clinical Trial Description

According to the National Cancer Institute (INCA), the estimate for Brazil, 2016-2017 biennium, points to the occurrence of about 600,000 new cases of cancer, and breast cancer (58000) in women will be the most frequent. One study revealed that only 12% of women undergoing chemotherapy in CM who participated in a physical exercise program had to readjusted the dose of the medications, while 34% of those who received the conventional treatment needed to readjust the Treatment doses, with neuropathy being one of the most present adverse effects that influenced this adjustment. In this sense, the conduct to keep the patient at rest during the treatment seems to potentiate her side effects, and sedentarism is another factor detrimental to the patient's health. Objective: To verify the effect of the intervention of a program of physical exercises and health education in women with breast cancer undergoing chemotherapy. Methodology: A sample will consist of 136 (136) Women, over 18 years of age, sedentary, diagnosed with non-metastatic breast cancer and initiating the first cycle of chemotherapy. They will be divided into two groups, randomly and stratified: control group: (CG n = 68) and exercise group: (eg n = 68) that will undergo a supervised training program of combined exercises for 24 weeks, with a frequency of 3 times Weekly and duration of 60 minutes, an unsupervised flexibility training program 2 times a week and both groups (GC and EG) will attend lectures on health education, which are held monthly. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04554823
Study type Interventional
Source Hospital Israelita Albert Einstein
Status Active, not recruiting
Phase N/A
Start date March 1, 2019
Completion date January 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04416087 - Exercise and Tumor Blood Flow in Breast Cancer Patients N/A
Active, not recruiting NCT04726319 - Family History App in Personalized Medicine N/A
Completed NCT04692168 - Influence of Chemotherapy on Postural Control in Women With Cancer
Recruiting NCT03709134 - Genomic Markers for Measuring Breast Cancer Response to Neoadjuvant Chemotherapy
Completed NCT03282214 - A Self-Management Energy Conservation Program for Cancer-Related Fatigue Phase 2
Recruiting NCT05711030 - Thoracic Paravertebral Block Anesthesia for Breast Cancer Surgery N/A
Suspended NCT03271853 - Thermalogical Analysis of a Cohort of Women and Men Undergoing Mammographic Analysis. N/A
Active, not recruiting NCT03144947 - Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients Phase 2
Completed NCT02996201 - Electronic Patient Reporting of Side Effects to Chemotherapy: A Cluster Randomized Controlled Trial N/A
Active, not recruiting NCT03282097 - Decisions About Cancer Screening in Alzheimer's Disease N/A
Recruiting NCT05573022 - Impact of a Patient Decision Aid Intervention N/A
Recruiting NCT05161312 - A Guided Online Intervention to Improve Quality of Life in Breast Cancer Patients - a Randomised Clinical Trial N/A
Active, not recruiting NCT04836221 - Comorbidities And Reducing inEquitieS N/A
Not yet recruiting NCT03910283 - Leveraging Mindsets to Improve Health & Wellbeing in Patients With Cancer N/A
Completed NCT03612934 - The Impact of SPC on Advanced Breast Cancer Patients
Recruiting NCT03301493 - Genomic Testing and Resulting Medical Decisions
Completed NCT04352530 - Culturally Appropriate Nutrition Communication for Mexican American Women N/A
Active, not recruiting NCT05830097 - A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT02991677 - Exercise Effect on Chemotherapy-Induced Neuropathic Pain N/A
Active, not recruiting NCT04971304 - Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars